TIL-ACT After NMA Chemo With IL-2 and Nivo Rescue in Metastatic Melanoma (mMEL)
Status:
Active, not recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This is a single center, single arm phase I trial to test the feasibility and safety of
Tumor- Infiltrating Lymphocyte-Adoptive Cell Therapy (TIL-ACT) followed by nivolumab rescue
in unresectable locally advanced or metastatic melanoma patients. The trial is based on
lymphodepleting chemotherapy followed by ACT, utilizing ex vivo expanded TILs in combination
with high dose interleukin-2 (IL-2) (optional, depending on patient's tolerance), followed by
nivolumab rescue (if indicated) for a maximum duration of 2 years.